Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
Press release – No. 18 / 2023 Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome Copenhagen, Denmark, December 22, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for glepaglutide, a long-acting GLP-2 analog, for th